Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab

Pembrolizumab is a programmed cell death protein 1 (PD-1) monoclonal antibody used in the treatment of metastatic melanomas. Severe ocular complications appear in less than 1% of the patients and require early treatment. We present the case of a patient diagnosed with a BRAF mutated metastatic melan...

Descripción completa

Detalles Bibliográficos
Autores principales: Navarro-Perea, Carmen, Garcia-Gonzalez, Javier, Perez-Blazquez, Eugenio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896544/
https://www.ncbi.nlm.nih.gov/pubmed/31755465
http://dx.doi.org/10.4103/ijo.IJO_1161_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896544/
https://www.ncbi.nlm.nih.gov/pubmed/31755465
http://dx.doi.org/10.4103/ijo.IJO_1161_19

Ejemplares similares